Allergic rhinitis
The impact of allergic rhinitis is enormous; it accounts for significant health morbidity and a large financial expenditure. It can occur at any age, but its peak onset is in childhood. The natural course of this atopic disorder varies, but tends to improve with time. Genetic and environmental factors play a role in its development. There are effective treatments including pharmacotherapy and immunotherapy. Allergen avoidance is difficult, but should be attempted. Future therapies will likely focus on downregulation of the Th2 immune phenotype and possibly upregulation of the Th1 response. Treating this condition is a daunting task; therefore, interventions to prevent atopy are appealing. Future therapies and studies will likely also focus on this issue. (c) 2001 Prous Science. All rights reserved.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2001 |
|---|---|
| Erschienen: |
2001 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 37(2001), 5 vom: 26. Mai, Seite 283-309 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reichmuth, Daniel [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM125342578 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM125342578 | ||
| 003 | DE-627 | ||
| 005 | 20231222205517.0 | ||
| 007 | tu | ||
| 008 | 231222s2001 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0418.xml |
| 035 | |a (DE-627)NLM125342578 | ||
| 035 | |a (NLM)12768218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reichmuth, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allergic rhinitis |
| 264 | 1 | |c 2001 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The impact of allergic rhinitis is enormous; it accounts for significant health morbidity and a large financial expenditure. It can occur at any age, but its peak onset is in childhood. The natural course of this atopic disorder varies, but tends to improve with time. Genetic and environmental factors play a role in its development. There are effective treatments including pharmacotherapy and immunotherapy. Allergen avoidance is difficult, but should be attempted. Future therapies will likely focus on downregulation of the Th2 immune phenotype and possibly upregulation of the Th1 response. Treating this condition is a daunting task; therefore, interventions to prevent atopy are appealing. Future therapies and studies will likely also focus on this issue. (c) 2001 Prous Science. All rights reserved | ||
| 650 | 4 | |a Journal Article | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 37(2001), 5 vom: 26. Mai, Seite 283-309 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2001 |g number:5 |g day:26 |g month:05 |g pages:283-309 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2001 |e 5 |b 26 |c 05 |h 283-309 | ||